The UK government has brought in pharma industry chiefs to co-chair a ministerial group aimed at ensuring Brexit does not damage the country’s life sciences sector.
Sir Andrew Witty and Pascal Soriot, the chief executives of GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN), the UK’s two largest pharma companies, are the co-chairmen of the 15-member group along with life sciences minister George Freeman.
The group held its first meeting last week as the UK starts considering the reality of Brexit, which a parliamentary committee had warned would hit the country’s life sciences sector hard before last month’s referendum.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze